ERYTECH announced that Pierre-Olivier Goineau will be leaving the company to pursue other interests. Pierre-Olivier Goineau was one of the co-founders of the company and has been instrumental in advancing the business both in terms of its operational and financial performance as co-founder and CEO and since 2013 as COO. The search for a replacement has been initiated. During the transition phase, Pierre-Olivier will continue to support the company on a consulting basis, notably in the continuation of the building of US operations.
PHAXIAM Therapeutics S.A. Euronext Paris
Equities
PHXM
FR0011471135
Biotechnology & Medical Research
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
1.984 EUR | -0.70% |
|
-0.40% | -53.33% |
07-03 | Phaxiam: EPIC Bpifrance exceeds 25% of share capital | CF |
06-28 | Would you like some more inflation? | ![]() |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+20.17% | 126B | |
+24.67% | 118B | |
+23.61% | 27.87B | |
-17.74% | 20.95B | |
-16.22% | 16.92B | |
-15.21% | 16.18B | |
+11.91% | 14.84B | |
-47.10% | 14.79B | |
+54.50% | 14.08B |
- Stock Market
- Equities
- PHXM Stock
- PHXM Stock
- News PHAXIAM Therapeutics S.A.
- Pierre-Olivier Goineau to Leave from ERYTECH as Co-Founder